within Pharmacolibrary.Drugs.ATC.L;

model L01XX62
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.57,
    Cl             = 0.28833333333333333,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.234,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Ivosidenib is an orally administered, small-molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme. It is approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. It is also used in patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced malignancies following oral administration of ivosidenib at the recommended dose (FDA label and population PK analysis).</p><h4>References</h4><ol><li><p>Fan, B, et al., &amp; Dai, D (2020). Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational new drugs</i> 38(2) 433–444. DOI:<a href=&quot;https://doi.org/10.1007/s10637-019-00771-x&quot;>10.1007/s10637-019-00771-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31028664/&quot;>https://pubmed.ncbi.nlm.nih.gov/31028664</a></p></li><li><p>Fan, B, et al., &amp; Yang, H (2024). Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study. <i>Cancer chemotherapy and pharmacology</i> 93(5) 471–479. DOI:<a href=&quot;https://doi.org/10.1007/s00280-023-04633-5&quot;>10.1007/s00280-023-04633-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38278871/&quot;>https://pubmed.ncbi.nlm.nih.gov/38278871</a></p></li><li><p>DiNardo, CD, et al., &amp; Kantarjian, HM (2018). Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. <i>The New England journal of medicine</i> 378(25) 2386–2398. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1716984&quot;>10.1056/NEJMoa1716984</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29860938/&quot;>https://pubmed.ncbi.nlm.nih.gov/29860938</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX62;
